A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection
PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
9
Participants
Timeline
Start Date
July 30, 2025
Primary Completion Date
July 30, 2026
Study Completion Date
July 30, 2027
Conditions
Chronic Hepatitis B Virus (Hbv)
Interventions
DRUG
WGc0201
Wgc0201 will be administered by intramuscular route, with a total of 9 doses.
All Listed Sponsors
collaborator
West China Hospital
OTHER
lead
Jiyan Liu
OTHER
NCT07051187 - A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection | Biotech Hunter | Biotech Hunter